Status and phase
Conditions
Treatments
About
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body).
The study has three parts:
All participants will receive the study drug PF-08046032. Only participants in Part B and Part C of the study will also receive sasanlimab. PF-08046032 will be given as an intravenous (IV) infusion, which means it will be injected directly into a vein. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histological or cytological diagnosis of metastatic or unresectable malignancy:
Measurable disease as defined by Lugano Classification for lymphomas or RECIST 1.1 for solid tumors
Able to provide tumor tissue(s) as defined by the protocol depending on the Part of the study at enrollment
ECOG Performance Status score 0 or 1
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
220 participants in 3 patient groups
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal